February 4, 2021 04:35 AM ESTUpdated 08:43 AM
Financing

Se­nior Ab­b­Vie li­ai­son quits job to launch neu­ro start­up, with sights set on ALS

Nicole DeFeudis

Editor

About a year ago, Howard Berman was sit­ting in a wait­ing room at Hous­ton Methodist Hos­pi­tal with his fa­ther, who was show­ing cog­ni­tive loss. They …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times